Latest TRPV1 Stories
SAN MATEO, Calif., April 28, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that it has received a Notice of Allowance from the U.S.
Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.
Research by a Barrow Neurological Institute scientist on the thermoregulatory effects of a receptor more commonly studied for its role in pain is the cover story in the Feb. 2 issue of the Journal of Neuroscience.
MUMBAI, India, August 31, 2010 /PRNewswire-FirstCall/ -- - With This Announcement, Glenmark has Clearly Reaffirmed its Position Globally as the Leader in the TRP Space Glenmark Pharmaceuticals today announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'.
For those with high blood pressure, chili peppers might be just what the doctor ordered.
Research led by a scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has opened the door for the advancement of a new category of painkillers, called TRPV1 antagonists.
ABBOTT PARK, Ill., Nov.
Scientists investigating the cough reflex have discovered a new group of molecules on the surface of nerve cells that make us cough when irritated.
General anaesthetic can make the pain of operations worse for patients recovering after surgery by activating the body's "mustard receptors", researchers have found. Many of the drugs that send surgical patients to sleep are known to make them more sensitive to pain when they wake up.
Anesthetics given to patients during surgery could cause an increase in pain following the procedure, according a new study.